1Boose D, Badgwell B, Cormier JN, et al. Association of neoadjuvant chemoradiation with improved survival in resectable gastric cancer. 2009 ASCO GI Cancers Symposium, Abstr 76.
2Mailey BA, Sun C, Artinyan A, et al. Relative outcomes for Asian - Americans with gastricarcinoma. 2009 ASCO GI Cancer Symposium, Abstr 3.
3Ott K, Becker K, Langer R, et al. Correlation of histopathological response to neoadjuvant chemotherapy (CTx) in the primary tumor and in lymph node mestastatic with outcome in 686 patients with gastric (GC) and esophageal adenocarcinoma (AEGI). 2009 ASCO GI Cancer Symposium, Abstr 42.
4Roth AD, Zalcberg JR, WU C, et al. Registryof gastric cancer treatment evaluation (REGATE). 2009 ASCO GI Cancer Symposium, Abstr 43.
5Terashima M, Bando E, Kawamura T, et al. Evaluation of the significace of lymph node staging for gastric cancer as a function of tumor location. 2009 ASCO GI Cancer Symposium, Abstr 56.
6Van de Velde CJH. Current role of surgery and multimodal treatment in localized gastric cancer [ J ]. Annals of Oncology, 2008, 19 (suppl 5): v93.
7Macdonald JS, Smalley S, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves disease - free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomuch and gastroesophageal junction: Updata of the resuh of intergroup study INT - 0116 (SWOG 9008). 2004 ASCO GI Cancer Symposium, Abstr 6.
8Cunningham D, Allum WH, Stenning SP, et al. Preoperative chemotherapy versus surgery alone for respectable gastroeophagerl cancer [ J ]. N Engl J Med, 2006, 255 (1):11.
9Ychou M, Pignon JP, Lasser P, et al. Phase III prelimminary results of preoperative fluorouracil (F) and cisplatin (P) versus surgery alone in adenocarcinoma of stumach and lower esophagus (ASLE): FNLCC 94012 - FFCD 9703 Trial [J]. JCO, 2006, 24 (18 suppl):4026.
10Cunningham D, Oliveira J. ESMO clinical recommendations for dignosis, treatment and follow - up [ J ]. Annals of Oncology, 2008, 19 (suppl 2): 123.
